In 117 people aged 1–55 with peanut plus ≥2 other food allergies, omalizumab beat omalizumab-facilitated multiallergen OIT for tolerating ≥4044 mg of all 3 foods (36% vs 19%; OR 2.6) by ITT but not per protocol; OIT had more serious adverse events (31% vs 0%).
RCTn = 117
Wood et al. Treatment of Multifood Allergy With Omalizumab or Multiallergen Oral Immunotherapy: A Randomized Clinical Trial